Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test
Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million ...
Wednesday, January 8, 2025
Tag: MidStage
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.